Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Anacin)
110,068 results
  • Recent patent applications for coffee and coffee byproducts as active ingredients in cosmetics. [Journal Article]
    Int J Cosmet Sci. 2023 Jan 26 [Online ahead of print]de Mello V, de Mesquita Júnior GA, … Vilela FMP
  • Coffee is one of the most consumed beverages worldwide, and its production and consumption generate large amounts of byproducts annually. Coffee byproducts and coffee beans are rich in bioactive compounds of great commercial value, including potential applications as active ingredients in skin care products and cosmetic formulations. In addition, there has been growing interest in the use of natu…
  • CYP1A2 Genetic Variation, Coffee Intake, and Kidney Dysfunction. [Journal Article]
    JAMA Netw Open. 2023 Jan 03; 6(1):e2247868.Mahdavi S, Palatini P, El-Sohemy A
  • CONCLUSIONS: In this study, the risks of albuminuria, hyperfiltration, and hypertension increased with heavy coffee intake only among those with the AC and CC genotypes of CYP1A2 at rs762551 associated with slow caffeine metabolism, suggesting that caffeine may play a role in the development of kidney disease in susceptible individuals.
  • Antithrombotic treatment after stroke due to intracerebral haemorrhage. [Review]
    Cochrane Database Syst Rev. 2023 Jan 26; 1:CD012144.Cochrane A, Chen C, … Al-Shahi Salman R
  • CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic treatment after ICH.
  • The striatum drives the ergogenic effects of caffeine. [Journal Article]
    Purinergic Signal. 2023 Jan 26 [Online ahead of print]de Bem Alves AC, Speck AE, … Aguiar AS
  • Caffeine is one of the main ergogenic resources used in exercise and sports. Previously, we reported the ergogenic mechanism of caffeine through neuronal A2AR antagonism in the central nervous system [1]. We now demonstrate that the striatum rules the ergogenic effects of caffeine through neuroplasticity changes. Thirty-four Swiss (8-10 weeks, 47 ± 1.5 g) and twenty-four C57BL/6J (8-10 weeks, 23.…
  • Thromboprophylaxis in Patients With Fontan Circulation. [Journal Article]
    J Am Coll Cardiol. 2023 Jan 31; 81(4):374-389.Van den Eynde J, Possner M, … Alsaied T
  • CONCLUSIONS: Aspirin, warfarin, and NOAC are associated with lower risk of thromboembolic events. Recognizing the limited number of patients and heterogeneity of studies using NOACs, the results support the safety and efficacy of NOACs in patients with a Fontan circulation.
  • Intravenous immunoglobulin for the treatment of Kawasaki disease. [Review]
    Cochrane Database Syst Rev. 2023 Jan 25; 1:CD014884.Broderick C, Kobayashi S, … Kobayashi T
  • CONCLUSIONS: The included RCTs investigated a variety of comparisons, and the small number of events observed during the study periods limited detection of effects. The certainty of the evidence ranged from moderate to very low due to concerns related to risk of bias, imprecision, and inconsistency. The available evidence indicated that high-dose IVIG regimens are probably associated with a reduced risk of CAA formation compared to ASA or medium- or low-dose IVIG regimens. There were no clinically significant differences in incidence of adverse effects, which suggests there is little concern about the safety of IVIG. Compared to ASA, high-dose IVIG probably reduced the duration of fever, but there was little or no difference detected in the need for additional treatment. Compared to medium- or low-dose IVIG, there may be reduced duration of fever and reduced need for additional treatment. We were unable to draw any conclusions regarding acute coronary syndromes, mortality, or length of hospital stay, or for the comparison IVIG versus prednisolone. Our findings are in keeping with current guideline recommendations and evidence from long-term epidemiology studies.
New Search Next